Results 41 to 50 of about 2,781,261 (274)

Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer’s disease dispensed by the Brazilian public health system – 2008 to 2014: a nation-wide analysis

Arquivos de Neuro-Psiquiatria
In light of the high cost of dementia treatment, there is legislation authorizing free distribution of cholinesterase inhibitors to those suffering from Alzheimer’s disease in Brazil.
Flávia Silva de Moraes, Mariana Lima Cerqueira de Souza, Giancarlo Lucchetti, Alessandra Lamas Granero Lucchetti   +3 more
doaj   +1 more source

Computer-aided approach for the identification of lead molecules as the inhibitors of cholinesterase’s and monoamine oxidases: Novel target for the treatment of Alzheimer disease [PDF]

Journal of the Serbian Chemical Society
Molecular docking is a promising and reliable technology for the purpose of discovering lead compounds via virtual screening. In addition to allowing for the testing of a large number of compounds, it also allows for the determination of how the selected
Ejaz Syeda Abida, Aziz Mubashir, Fayyaz Ammara, Wani Tanveer A., Zargar Seema   +4 more
doaj   +1 more source

Inhibitory effect of benzimidazole derivatives on cholinesterases of animals in the presence of different substrates [PDF]

The Ukrainian Biochemical Journal, 2014
Specifically synthesized group of benzimid­azole derivatives possessing varying degrees of delocalization of the positive charge in the cation group of the molecule has been studied in order to search for potential cholinergically active compounds and to
N. E. Basova, B. N. Kormilitsyn, A. Yu. Perchenok,, E. V. Rozengart, V. S. Saakov, A. A. Suvorov   +5 more
doaj   +1 more source

Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement

Biomolecules, 2019
Alzheimer’s disease, a major and increasing global health challenge, is an irreversible, progressive form of dementia, associated with an ongoing decline of brain functioning.
Gabriela Dumitrita Stanciu, Andrei Luca, Razvan Nicolae Rusu, Veronica Bild, Sorin Ioan Beschea Chiriac, Carmen Solcan, Walther Bild, Daniela Carmen Ababei   +7 more
doaj   +1 more source

Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.

PLoS ONE, 2014
Patients with Alzheimer's disease after an initial response to cholinesterase inhibitors may complain a later lack of efficacy. This, in association with incident neuropsychiatric symptoms, may worsen patient quality of life.
Gianfranco Spalletta, Carlo Caltagirone, Alessandro Padovani, Sandro Sorbi, Mahmood Attar, Delia Colombo, Luca Cravello, E V O L U T I O N study Working Group   +7 more
doaj   +1 more source

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis

Experimental and Therapeutic Medicine, 2018
Recently, several randomized controlled trials on the use of cholinesterase inhibitors or memantine as treatments for cognitive impairment in Parkinson's disease (CIND-PD), Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) were ...
Y. Meng, Panpan Wang, Yaxue Song, Jianhua Wang   +3 more
semanticscholar   +1 more source

Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors

Biomolecules, 2019
Tacrine was the first drug to be approved for Alzheimer’s disease (AD) treatment, acting as a cholinesterase inhibitor. The neuropathological hallmarks of AD are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration.
B. Svobodova, E. Mezeiova, Vendula Hepnarova, M. Hrabinová, Ľ. Múčková, T. Kobrlova, D. Jun, O. Soukup, M. Jimeno, J. Marco-Contelles, J. Korábečný   +10 more
semanticscholar   +1 more source

Cholinesterases and Their Inhibitors

, 2022
The main focus of this section is to review the available information on ChEs (ChEs) and their inhibitors. The ChE enzymes cause damage to the cholinergic system by hydrolyzing the neurotransmitter acetylcholine (ACh). ChE inhibitors, playing an important role in the cholinergic system, are used in the treatment of Alzheimer’s disease (AD) because of ...
openaire   +2 more sources

Cholinergic Degeneration and Cognitive Function in Early GBA1‐Related Parkinson's Disease

Annals of Neurology, EarlyView.
Objective The phenotype of patients with Parkinson's disease carrying GBA1 variants (GBA‐PD) suggest similarities to symptomatology associated with early cholinergic system degeneration. Therefore, this study aims to investigate the clinical features and the cholinergic innervation pattern in patients with early GBA‐PD versus those without the GBA1 ...
Sofie Slingerland, Sygrid van der Zee, Giulia Carli, Anne C. Slomp, Emile d'Angremont, Jeffrey M. Boertien, Teus van Laar   +6 more
wiley   +1 more source

The effects of novel 7-MEOTA-donepezil like hybrids and N-alkylated tacrine analogues in the treatment of quinuclidinyl benzilate-induced behavioural deficits in rats performing the multiple T-maze test

Biomedical Papers, 2015
Aims: The number of approved drugs for the clinical treatment of Alzheimer disease remains limited. For this reason, there is extensive search for novel therapies.
Jan Misik, Jan Korabecny, Eugenie Nepovimova, Pavla Cabelova, Jiri Kassa   +4 more
doaj   +1 more source